PharmaShots | Incisive News in 3 Shots

Subscribe Now

Validation

Gilead Reports EMA's Validation of MAA for Lenacapavir to Treat HIV-1 in People with Limited Therapy Options

Gilead Reports EMA's Validation of MAA for Lenacapavir to Treat HIV-1 in People with Limited Therapy Options

August 20, 2021

BMS Reports EMA's Validation of MAA for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + CT to Treat Esophageal Squamous Cell Carcinoma

BMS Reports EMA's Validation of MAA for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + CT to Treat Esophageal Squamous Cell...

August 17, 2021

Daiichi Reports EMA's Validation of MAA and Accelerated Assessment for Trastuzumab Deruxtecan to Treat HER2 Positive Metastatic Breast Cancer

Daiichi Reports EMA's Validation of MAA and Accelerated Assessment for Trastuzumab Deruxtecan to Treat HER2 Positive Metastatic Br...

July 7, 2020

Merck KGaA and Pfizer Report EMA's Validation for Bavencio (avelumab) as a 1L Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Merck KGaA and Pfizer Report EMA's Validation for Bavencio (avelumab) as a 1L Treatment for Locally Advanced or Metastatic Urothel...

June 22, 2020

BMS Reports EMA's Validation of MAA for Idecabtagene Vicleucel (Ide-cel- bb2121) and CC-486

BMS Reports EMA's Validation of MAA for Idecabtagene Vicleucel (Ide-cel- bb2121) and CC-486

May 22, 2020

$Kite Reports the Validation of EMA's MAA for KTE-X19 to Treat Relapsed or Refractory Mantle Cell Lymphoma$

Kite Reports the Validation of EMA's MAA for KTE-X19 to Treat Relapsed or Refractory Mantle Cell Lymphoma

January 29, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us